Cardinal Health

Belkins
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #15 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INTEC PHARMA ANNOUNCES NEW RESEARCH COLLABORATION AGREEMENT WITH MSD

Intec Pharma | October 08, 2020

news image

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows t...

Read More

PHARMACY MARKET

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals | November 20, 2021

news image

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More

USA TO DO A CLINICAL TEST OF THE JAPANESE ANTI-FLU DRUG AVIGAN TO TREAT THE PATIENTS SUFFERING FROM CORONAVIRUS

Clout News | April 12, 2020

news image

The number of positive cases of coronavirus are on a rising spree all over the world. The confirmed cases of COVID-19 on a global scale have crossed 1.7 million with the death toll crossing 1,08,000. The most affected country because of coronavirus is the United States of America. With around 5,33,378 positive cases in USA, its death toll has reached more than 20,600 leaving Italy’s death toll behind. According to the reports, USA recorded over 2,000 deaths because of COVID-19. The country...

Read More

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

Fiercepharma | June 10, 2020

news image

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More

Intec Pharma | October 08, 2020

news image

INTEC PHARMA ANNOUNCES NEW RESEARCH COLLABORATION AGREEMENT WITH MSD

Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows t...

Read More

PHARMACY MARKET

EyePoint Pharmaceuticals | November 20, 2021

news image

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More

Clout News | April 12, 2020

news image

USA TO DO A CLINICAL TEST OF THE JAPANESE ANTI-FLU DRUG AVIGAN TO TREAT THE PATIENTS SUFFERING FROM CORONAVIRUS

The number of positive cases of coronavirus are on a rising spree all over the world. The confirmed cases of COVID-19 on a global scale have crossed 1.7 million with the death toll crossing 1,08,000. The most affected country because of coronavirus is the United States of America. With around 5,33,378 positive cases in USA, its death toll has reached more than 20,600 leaving Italy’s death toll behind. According to the reports, USA recorded over 2,000 deaths because of COVID-19. The country...

Read More

Fiercepharma | June 10, 2020

news image

MODERNA, ASTRAZENECA AND J&J CORONAVIRUS SHOTS REV UP FOR NIH TESTS BEGINNING IN JULY: WSJ

As leading coronavirus vaccines make their way through early stages of human testing, the NIH is plotting much larger efficacy studies this summer. U.S. researchers plan to run phase 3 trials of vaccines from Moderna, AstraZeneca and Johnson & Johnson in the coming months, the Wall Street Journal reports. The NIH intends to start a phase 3 trial of Moderna’s vaccine in July, followed by an August trial of AstraZeneca’s vaccine and a September study of Johnson & Johnson&...

Read More